Locations:
Search IconSearch
April 4, 2018/Neurosciences

PACNS or RCVS? Differences in Clinical Presentation

How to tell the difference and why it matters

16-RHE-871-Calabrese-Hero-Image-650x450pxl

By Rula Hajj-Ali, MD, and Leonard Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Primary angiitis of the central nervous system (PACNS) is a devastating disease in which exclusive inflammation and destruction of vessels in the CNS cause progressive, debilitating neurological deficits. Prognosis improves greatly with proper treatment, but with nonspecific tests and many confounding mimics, diagnosis can be tricky.

One of PACNS’s closest mimics is reversible cerebral vasoconstriction syndrome (RCVS). The distinguishing characteristic of this group is the “thunderclap” headache — sudden, severe and with or without neurological deficits. Originally, rheumatologists treated RCVS as benign angiopathy of the CNS. In 2007, Calabrese et al set forth RCVS as a concept encompassing several syndromes with unifying clinical, laboratory and radiologic features. The clinical features and diagnostic criteria described in that paper have been considered the standard since its publication.

Distinguishing between RCVS and PACNS is critical because the treatment protocol is so vastly different. Misdiagnosing PACNS as RCVS can deprive a patient of medications that prolong survival and improve outcomes. These conditions are close mimics, but the astute clinician has several tools in her armamentarium to distinguish between them. We offer a brief overview of differences in clinical presentation below. Future posts will discuss differences in test results and management.

Clinical presentation

Patients with PACNS are more commonly male and trend older with a mean age of 50 years at onset, while patients with RCVS are more likely to be female and a bit younger. Patients with both conditions almost always present with headaches, but the differences in onset and type are important to distinguish between the mimics. Patients with PACNS experience subacute onset of headaches with focal and nonfocal deficits; a patient with sudden-onset, severe, “thunderclap” headaches should be considered for RCVS whether or not neurological deficits are present. RCVS is monophasic, but patients with PACNS will experience these symptoms chronically.

Advertisement

When patients present with these symptoms, diagnostic tests can help eliminate the mimics and narrow towards a precise diagnosis.

Dr. Hajj-Ali is Associate Director of the Center for Vasculitis Care and Research in the Department of Rheumatic and Immunologic Diseases. Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology.

Advertisement

Related Articles

Portrait of Dr. Oguh
Ataxia: A Symptom That Points to the Need for a Deeper Dive (Podcast)

Multidisciplinary care can be key to managing challenging condition

pathology slice of human spinal cord
Unmasking Spinal Cord Pathology in MS: 7T MRI Reveals Neurodegeneration Beyond Demyelination

Novel insights from a postmortem study combining imaging, pathology and clinical perspectives

Man with leg prosthetic tying shoe
April 29, 2025/Neurosciences
QUEST Study: Self-Administered High-Frequency Nerve Block Effective for Postamputation Pain

Relieves discomfort, reduces opioid dependency and improves quality of life

Dr. Robert Fox against a decorative background with a podcast icon overlay
April 16, 2025/Neurosciences/Podcast
Emerging Therapeutic Options in Progressive Multiple Sclerosis (Podcast)

Long-awaited efficacy against disability progression appears to be at hand

medication vials, syringes, tablets and capsules on a tabletop
Early Intensive or Escalation Therapy for Relapsing-Remitting Multiple Sclerosis?

Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies

illustration of brain plus chemical diagram of tavapadon
April 11, 2025/Neurosciences/Research
TEMPO: Tavapadon Shows Promise as Both First and Adjunct Therapy in Parkinson’s

Dopamine agonist performs in patients with early stage and advanced disease

Illustration of head and brain to depict migraine pain
Transnasal Evaporative Cooling Effective for Acute Treatment of Migraine Pain

A flow of dehumidified room air delivered via at-home device modulates sphenopalatine ganglion

hand pointing at brain scans on a computer monitoring
Disability Progression Slowed for First Time in Nonrelapsing Secondary Progressive Multiple Sclerosis

BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial

Ad